Article Details

Mortality benefit in COVID-19 from interleukin-6 antagonists

Retrieved on: 2021-07-09 09:33:45

Tags for this article:

Click the tags to see associated articles and topics

Mortality benefit in COVID-19 from interleukin-6 antagonists. View article details on hiswai:

Excerpt

The interleukin-6 antagonists that have received most attention are the monoclonal antibodies, tocilizumab and sarilumab, which either bind directly to ...

Article found on: hospitalhealthcare.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up